SV2010003779A - Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh - Google Patents
Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vhInfo
- Publication number
- SV2010003779A SV2010003779A SV2010003779A SV2010003779A SV2010003779A SV 2010003779 A SV2010003779 A SV 2010003779A SV 2010003779 A SV2010003779 A SV 2010003779A SV 2010003779 A SV2010003779 A SV 2010003779A SV 2010003779 A SV2010003779 A SV 2010003779A
- Authority
- SV
- El Salvador
- Prior art keywords
- hydrogen
- rent
- compounds
- type193
- cyclopropil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
LOS COMPUESTOS DE FÓRMULA I: (VER FORMULA); DONDE: R2 ES HIDRÓGENO O ALQUILO C1-C4; R3 Y R4 SON HIDRÓGENO, -C(=O)R5, O -C(=O)CHR6-NH2; O R3 ES HIDRÓGENO Y R4 ES UN ÉSTER DE MONOFOSFATO, DIFOSFATO, O TRIFOSFATO; O R3 ES HIDRÓGENO, -C(=O)CHR5, O -C(=O)CHR6-NH2 Y R4 ES (VER FORMULA); CADA R5 ES HIDRÓGENO, ALQUILO C1-C6, O CICLOALQUILO C3-C7; R6 ES HIDRÓGENO O ALQUILO C1-C6; R7 ES FENILO OPCIONALMENTE SUSTITUIDO; NAFTILO; O INDOLILO; R8 Y R8' SON HIDRÓGENO, ALQUILO C1-C6, BENCILO; O R8 Y R8' COMBINADOS FORMAN CICLOALQUILO C3-C7; R9 ES ALQUILO C1-C6, BENCILO, O FENILO OPCIONALMENTE SUSTITUIDO; SIEMPRE QUE R2, R3 Y R4 NO SEAN TODOS HIDRÓGENO; O SU SAL O SOLVATO ACEPTABLE PARA USO FARMACÉUTICO; FORMULACIONES FARMACÉUTICAS CON LOS COMPUESTOS I; EL USO DE COMPUESTOS I, INCLUYENDO LOS COMPUESTOS DE FÓRMULA I DONDE R2, R3 Y R4 SON TODOS HIDRÓGENO, COMO INHIBIDORES DEL VHC
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08159396 | 2008-07-01 | ||
EP08171005 | 2008-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2010003779A true SV2010003779A (es) | 2011-02-08 |
Family
ID=41095413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2010003779A SV2010003779A (es) | 2008-07-01 | 2010-12-22 | Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh |
Country Status (29)
Country | Link |
---|---|
US (1) | US8431588B2 (es) |
EP (1) | EP2141172B1 (es) |
JP (1) | JP5624029B2 (es) |
KR (1) | KR20110038683A (es) |
CN (2) | CN105693794A (es) |
AP (1) | AP2010005505A0 (es) |
AR (1) | AR072428A1 (es) |
AU (1) | AU2009266004B2 (es) |
BR (1) | BRPI0913643A2 (es) |
CA (1) | CA2729316A1 (es) |
CL (1) | CL2010001634A1 (es) |
CO (1) | CO6321255A2 (es) |
DK (1) | DK2141172T3 (es) |
EA (1) | EA022754B1 (es) |
EC (1) | ECSP10010725A (es) |
ES (1) | ES2396803T3 (es) |
HK (1) | HK1226080A1 (es) |
HR (1) | HRP20121068T1 (es) |
IL (1) | IL209932A (es) |
MX (1) | MX2010014493A (es) |
NI (1) | NI201000231A (es) |
PL (1) | PL2141172T3 (es) |
PT (1) | PT2141172E (es) |
SI (1) | SI2141172T1 (es) |
SV (1) | SV2010003779A (es) |
TW (1) | TW201012814A (es) |
UY (1) | UY31950A (es) |
WO (1) | WO2010000459A1 (es) |
ZA (1) | ZA201009294B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089887B1 (ko) * | 2008-09-08 | 2020-03-16 | 사우디 아람코 테크놀로지스 컴퍼니 | 폴리카보네이트 폴리올 조성물 |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제 |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5845841B2 (ja) | 2011-11-18 | 2016-01-20 | 東芝ライテック株式会社 | 照明制御装置 |
AU2013221571A1 (en) | 2012-02-14 | 2014-08-28 | University Of Georgia Research Foundation, Inc. | Spiro [2.4] heptanes for treatment of Flaviviridae infections |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
IL295418B2 (en) | 2015-03-06 | 2023-10-01 | Atea Pharmaceuticals Inc | Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus |
RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
KR102335193B1 (ko) | 2017-02-01 | 2021-12-03 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100333016B1 (ko) | 1992-12-29 | 2002-11-22 | 아보트 러보러터리즈 | 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물 |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
DE14169110T1 (de) | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
CA2523083C (en) * | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
CA2577526A1 (en) * | 2004-08-23 | 2006-03-02 | Joseph Armstrong Martin | Antiviral 4'-azido-nucleosides |
JP2010505902A (ja) * | 2006-10-10 | 2010-02-25 | メディヴィル・アクチエボラーグ | Hcvヌクレオシド阻害剤 |
-
2009
- 2009-06-30 UY UY0001031950A patent/UY31950A/es unknown
- 2009-06-30 TW TW098121932A patent/TW201012814A/zh unknown
- 2009-06-30 AR ARP090102442A patent/AR072428A1/es not_active Application Discontinuation
- 2009-07-01 WO PCT/EP2009/004748 patent/WO2010000459A1/en active Application Filing
- 2009-07-01 AU AU2009266004A patent/AU2009266004B2/en not_active Ceased
- 2009-07-01 PT PT90086349T patent/PT2141172E/pt unknown
- 2009-07-01 MX MX2010014493A patent/MX2010014493A/es active IP Right Grant
- 2009-07-01 EP EP09008634A patent/EP2141172B1/en active Active
- 2009-07-01 KR KR1020117002345A patent/KR20110038683A/ko not_active Application Discontinuation
- 2009-07-01 BR BRPI0913643A patent/BRPI0913643A2/pt not_active IP Right Cessation
- 2009-07-01 US US12/999,263 patent/US8431588B2/en not_active Expired - Fee Related
- 2009-07-01 CN CN201610033092.2A patent/CN105693794A/zh active Pending
- 2009-07-01 AP AP2010005505A patent/AP2010005505A0/xx unknown
- 2009-07-01 EA EA201170118A patent/EA022754B1/ru not_active IP Right Cessation
- 2009-07-01 CN CN200980125579.1A patent/CN102083845B/zh not_active Expired - Fee Related
- 2009-07-01 ES ES09008634T patent/ES2396803T3/es active Active
- 2009-07-01 PL PL09008634T patent/PL2141172T3/pl unknown
- 2009-07-01 JP JP2011515237A patent/JP5624029B2/ja not_active Expired - Fee Related
- 2009-07-01 SI SI200930467T patent/SI2141172T1/sl unknown
- 2009-07-01 DK DK09008634.9T patent/DK2141172T3/da active
- 2009-07-01 CA CA2729316A patent/CA2729316A1/en not_active Abandoned
-
2010
- 2010-12-12 IL IL209932A patent/IL209932A/en not_active IP Right Cessation
- 2010-12-22 SV SV2010003779A patent/SV2010003779A/es not_active Application Discontinuation
- 2010-12-23 CO CO10161808A patent/CO6321255A2/es not_active Application Discontinuation
- 2010-12-23 ZA ZA2010/09294A patent/ZA201009294B/en unknown
- 2010-12-23 NI NI201000231A patent/NI201000231A/es unknown
- 2010-12-29 EC EC2010010725A patent/ECSP10010725A/es unknown
- 2010-12-30 CL CL2010001634A patent/CL2010001634A1/es unknown
-
2012
- 2012-12-27 HR HRP20121068AT patent/HRP20121068T1/hr unknown
-
2016
- 2016-12-15 HK HK16114266A patent/HK1226080A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2010003779A (es) | Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh | |
UY32308A (es) | Nucleótidos uracil ciclopropílicos | |
CO6440533A2 (es) | Nucleósidos espiro oxetánicos uracílicos | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
UY31606A1 (es) | Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica | |
AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
BR112014014909A2 (pt) | agonistas de tgr5 não sistêmicos | |
AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
EA201290520A1 (ru) | Производные дифенилпиразолопиридинов, их получение и применение в качестве модуляторов нуклеарного рецептора not | |
CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
PA8776401A1 (es) | Nuevos compuestos hetericiclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
UY32632A (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica. | |
ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
AR088414A1 (es) | Derivados sustituidos de indol | |
CU20220023A7 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |